Provides advice, guidance and counsel on sales and marketing strategies, programs, policies, practices and initiatives with respect to applicable healthcare laws, regulations, guidance, government enforcement positions and industry codes, including the FDCA, FDA guidance, fraud and abuse laws, anti-kickback statutes, federal and state transparency laws, OIG Advisory Opinions and the PhRMA Code. With multiple marketed medicines and a leading pipeline in neurology, cardiology and select areas of high patient needs, we continue to drive innovation in RNA therapies in addition to advancing new approaches in gene editing to provide greater value to patients and are well positioned financially to deliver on our strategic goals.